FOLD - Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual Congress of the World Muscle Society (WMS) , being held October 3-7, 2023 in Charleston, SC.
Oral Presentation:
Abstract Title: 104-week efficacy and safety of cipaglucosidase alfa + miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa (Oral #O21)
- Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
- Date and time: Saturday, October 7, 7:45-8:45 a.m. E.T.
- Location: PAC, Charleston Area Convention Center
Poster Sessions:
Abstract Title: Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease (Poster #P371)
- Presenter: Kristl G. Claeys, MD, PhD, University Hospitals Leuven, Leuven, Belgium
- Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Ballroom A-C, Charleston Area Convention Center
Abstract Title: Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL (Poster #P373)
- Presenter: Jordi Díaz-Manera, MD, PhD, John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne, U.K.
- Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Ballroom A-C, Charleston Area Convention Center
Abstract Title: Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials (Poster #P372)
- Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.
- Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Ballroom A-C, Charleston Area Convention Center
Abstract Title: Disease burden, treatment patterns and healthcare resource utilization associated with Pompe disease in Sweden: a real-world evidence study (ePoster #VP369)
- Presenter: Christopher Lindberg, MD, Neuromuscular Centre, Sahlgrenska University Hospital, Gothenburg, Sweden
- Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Virtual Platform
For more information on the World Muscle Society 2023, please visit wms2023.com .
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com , and follow on Twitter and LinkedIn .
CONTACTS:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G